What are the key drivers for selecting ideal RRMM patients for treatment with bispecific antibodies?

Learning objective:

After participating in this webinar, viewers should be able to:

• Explain what the key drivers are when selecting RRMM patients for treatment with bispecific antibodies

Faculty:

• Michel Delforge (Belgium)
• Paula Rodriguez-Otero (Spain)
• Philippe Moreau (France)